Fulltext

Seroprevalence and incidence of hepatitis A in Southeast Asia: A systematic review

Hernandez-Suarez G 1 , Saha D 1 , Lodroño K 2 , Boonmahittisut P 3 , Taniwijaya S 4 , Saha A 5 Show all authors , Badur S 6 , Poovorawan Y 7

Affiliations 

  • 1 GSK, Medical & Clinical Emerging Markets, Wavre, Belgium
  • 2 GSK, Medical Affairs Philippines, Manila, The Philippines
  • 3 GSK, Thailand Vaccines, Bangkok, Thailand
  • 4 GSK, Medical & Clinical Emerging Markets, Jakarta, Indonesia
  • 5 GSK, Vaccines Medical, Kuala Lumpur, Malaysia
  • 6 GSK, Medical & Clinical Emerging Markets, Istanbul, Turkey
  • 7 Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
PLoS One, 2021;16(12):e0258659.
PMID: 34851983 DOI: 10.1371/journal.pone.0258659

Abstract

BACKGROUND: A previous review on hepatitis A virus (HAV) seroprevalence in 2005 categorized Southeast Asia as a low HAV endemicity region. In 2010, the World Health Organization modified this from low to low/medium endemicity, pointing out that these estimates were based on limited evidence. Since then, there has been no attempt to review HAV epidemiology from this region. We conducted a systematic review of literature to collect information on HAV incidence and seroprevalence in select countries in the Southeast Asian region, specifically, The Association of Southeast Asian Nations over the last 20 years.

METHODOLOGY: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. From the relevant articles, we extracted data and conducted a risk of bias assessment of individual studies.

RESULTS: The search yielded 22 and 13 publications on HAV seroprevalence and incidence, respectively. Overall, our findings point to a very low HAV endemicity profile in Thailand and Singapore and evidence of a shift towards low HAV endemicity in Indonesia, Lao People's Democratic Republic, Malaysia, the Philippines, and Vietnam. Only Singapore, Thailand, Malaysia, and the Philippines have existing HAV disease surveillance and reported incidence rates below 1 per 100,000. Several outbreaks with varying magnitude documented in the region provide insights into the evolving epidemiology of HAV in the region. Risk of bias assessment of studies revealed that the individual studies were of low to medium risk.

CONCLUSIONS/SIGNIFICANCE: The available HAV endemicity profiles in Southeast Asian countries, aside from Thailand, are limited and outdated, but suggest an endemicity shift in the region that is not fully documented yet. These findings highlight the need to update information on HAV epidemiology through strengthening of disease surveillance mechanisms to confirm the shift in HAV endemicity in the region.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications